GlaxoSmithKline plc (LON:GSK) insider Victoria Whyte acquired 8 shares of the company’s stock in a transaction that occurred on Wednesday, November 9th. The stock was acquired at an average price of GBX 1,593 ($19.73) per share, with a total value of £127.44 ($157.86).

Shares of GlaxoSmithKline plc (LON:GSK) opened at 1573.50 on Friday. The firm’s market capitalization is GBX 76.57 billion. GlaxoSmithKline plc has a 1-year low of GBX 1,277.25 and a 1-year high of GBX 1,745.56. The firm’s 50 day moving average is GBX 1,642.88 and its 200 day moving average is GBX 1,582.95.

Insider Buying and Selling by Quarter for GlaxoSmithKline plc (LON:GSK)

The business also recently announced a dividend, which will be paid on Thursday, January 12th. Shareholders of record on Thursday, November 3rd will be paid a GBX 19 ($0.24) dividend. This represents a yield of 1.17%. The ex-dividend date is Thursday, November 3rd.

Several research firms have commented on GSK. Credit Suisse Group AG reiterated a “neutral” rating and set a GBX 1,800 ($22.30) price target on shares of GlaxoSmithKline plc in a report on Thursday, July 14th. S&P Global Inc. set a GBX 1,650 ($20.44) price target on shares of GlaxoSmithKline plc and gave the stock a “neutral” rating in a report on Wednesday, July 27th. BNP Paribas reiterated a “neutral” rating on shares of GlaxoSmithKline plc in a report on Friday, July 29th. Goldman Sachs Group Inc. reiterated a “buy” rating and set a GBX 1,800 ($22.30) price target on shares of GlaxoSmithKline plc in a report on Thursday, October 27th. Finally, Citigroup Inc. set a GBX 1,800 ($22.30) price target on shares of GlaxoSmithKline plc and gave the stock a “buy” rating in a report on Thursday, September 29th. Two equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and nine have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of GBX 1,723.54 ($21.35).

About GlaxoSmithKline plc

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

Receive News & Stock Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related stocks with our FREE daily email newsletter.